RecruitingNCT04088422

Cell Free DNA in Mature B-cell Lymphoma

Prospective, Observational Study on Cell Free DNA Genotyping as a Tool to Inform Mature B-cell Lymphoma Management

Sponsor

Ruijin Hospital

Enrollment

320 participants

Start Date

Sep 28, 2022

Study Type

OBSERVATIONAL

Conditions

Mature B-Cell Lymphoma

Summary

The purpose of this study is to assess whether plasma cell free DNA is an accurate tool that can early and dynamically inform on treatment outcome and an accessible source of tumor DNA to track tumor clonal evolution.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting blood and tissue samples from patients newly diagnosed with mature B-cell lymphoma (a type of blood cancer). Researchers will measure cell-free DNA — tiny fragments of tumor DNA circulating in the blood — to understand the cancer better and potentially develop new tools for monitoring treatment response. **You may be eligible if...** - You have been diagnosed with a mature B-cell tumor (confirmed by a doctor) - You are 18 or older **You may NOT be eligible if...** - You have already received chemotherapy for this lymphoma - You have another active cancer Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREperipheral blood collection

peripheral blood collection at treatment start, interm PET/CT, end of treatment PET/CT, one-year and two-year follow-up and or progression or relapse

Locations(1)

Ruijin hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04088422